TABLE 1.
Serum microRNAs for diagnosis and stage of liver fibrosis
| Number | MicroRNA | Diseases | Country | Fibrosis diagnostic method | Expression/source | Cohort | AUC for fibrosis | AUC for early fibrosis | AUC for late fibrosis | AUC for stage fibrosis or late fibrosis | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | microRNA21 | CHB | China | Liver biopsy | Up/serum | 28 | NT | NT | NT | 0.64 | 16 |
| AIH | America | Liver biopsy | Up/serum | 46 | NT | NT | NT | NT | 17 | ||
| CHB | China | Liver biopsy | Up/serum | 123 | NT | NT | NT | 0.7589 | 18 | ||
| 2 | MicroRNA122 | CHC | Egypt | Liver biopsy | Up/serum | 40 | NT | 1.0 | NT | Can not | 25 |
| CHC | German | Liver biopsy | Up/serum | 68 | NT | NT | NT | Can not | 26 | ||
| CHB | Japan | Liver biopsy | Up/serum | 91 | NT | NT | NT | 0.668 | 27 | ||
| MAFLD | Egypt | Fibro‐scan | Up/serum | 120 | NT | NT | NT | NT | 28 | ||
| 3 | let‐7a‐5p | CHC | Japan | Liver biopsy | Up/serum | 84 | NT | NT | NT | 0.892 | 30 |
| schistosomiasis infected patients | Australia | Ultrasound | NT/serum | 163 | NT | NT | NT | 0.6598 | 31 | ||
| 4 | let‐7d‐5p | schistosomiasis infected patients | Australia | Ultrasound | NT/serum | 163 | NT | NT | NT | 0.6270 | 31 |
| 5 | microRNA214 | Biliary atresia | Japan | Liver biopsy | NT/serum | 28 | NT | NT | NT | 0.805 | 33 |
| 6 | microRNA155 | NT(liver cirrhosis) | China | Liver biopsy | NT//plasma exsosomes | 94 | NT | NT | 0.971 | NT | 40 |
| CHC | Egypt | Liver biopsy | NT/serum | 145 | NT | NT | NT | Can not | 41 | ||
| 7 | MicroRNA29a | NT | Germany | NT | Down/serum | 67 | NT | NT | 0.838 | NT | 46 |
| CHC,CHB | France | NT | Down in severe fibrosis /serum | 72,83 | NT | NT | NT | NT | 47 | ||
| 8 | MicroRNA‐1373g‐3p | CHC | China | Liver biopsy | Up in moderate to severe fibrosis compared to mild fibrosis/serum | 61 | NT | NT | NT | 0.790 | 49 |
| CHC | China | Liver biopsy | Up in moderate to severe fibrosis compared to mild fibrosis/serum | 112 | NT | NT | NT | 0.841‐0.933 | 50 | ||
| 9 | MicroRNA34a | CHC | China | Liver biopsy | Up/serum | 41 | NT | 0.8274 | 0.8904 | NT | 54 |
| 10 | MicroRNA17 | CHB | China | Liver biopsy | Up/serum | 200 | NT | 0.685 | 0.9169 | NT | 58 |
| 11 | MicroRNA20a | CHC | America | Liver biopsy | Up/serum | 44 | 0.704 | NT | NT | NT | 60 |
| 12 | MicroRNA138 | CHC | Egypt | Liver biopsy | Up/serum | 71 | NT | 0.866 | 0.924 | NT | 63 |
| 13 | microRNA150‐5p | schistosomiasis infected patients | Australia | Ultrasonography | Down in severe fibrosis compared to mild fibrosis/serum | 163 | NT | NT | NT | 0.6838 | 31 |
| 14 | microRNA146a‐5p | schistosomiasis infected patients | Australia | Ultrasonography | Down in severe fibrosis compared to mild fibrosis/serum | 163 | NT | NT | NT | 0.6575 | 31 |
| schistosomiasis infected patients | Australia | Ultrasound | Down/serum exosomes | 104 | 0.6315 | NT | NT | NT | 64 | ||
| 15 | microRNA532‐5p | schistosomiasis infected patients | Australia | Ultrasound | Down/serum exosomes | 104 | 0.6884 | NT | NT | NT | 64 |
| 16 | MicroRNA29b | CHB | China | Liver biopsy | Down in severe fibrosis compared to mild fibrosis/serum | 123 | NT | NT | NT | 0.7237 | 18 |
| 17 | MicroRNA29c | CHB | China | Liver biopsy | Down in severe fibrosis compared to mild fibrosis/serum | 123 | NT | NT | NT | 0.8121 | 18 |
| 18 | MicroRNA143 | CHB | China | Liver biopsy | Down in severe fibrosis compared to mild fibrosis/serum | 123 | NT | NT | NT | 0.8123 | 18 |
| 19 | MicroRNA223 | CHB | China | Liver biopsy | Down in severe fibrosis compared to mild fibrosis/serum | 123 | NT | NT | NT | 0.7806 | 18 |
| 20 | MicroRNA374 | CHB | China | Liver biopsy | Down in severe fibrosis compared to mild fibrosis/serum | 123 | NT | NT | NT | 0.7282 | 18 |
Abbreviations: CHB, chronic HBV hepatitis; CHC, chronic HCV hepatitis; MAFLD, metabolic‐associated fatty liver disease; NT, Not mentioned.